INTERNATIONAL JOURNAL
OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206
Volume 5, September ,2025
10
NON-ALCOHOLIC FATTY LIVER DISEASE: PATHOGENESIS,
HISTOPATHOLOGICAL FEATURES, AND CLINICAL IMPLICATIONS
Manekshal Bitsh
Independent researcher of medical centre in Dehli, India
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a major hepatological disorder
characterized by excessive fat accumulation in hepatocytes without significant alcohol
consumption. It represents the most common cause of chronic liver disease worldwide, affecting
nearly one quarter of the global population. NAFLD encompasses a spectrum ranging from
simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. This article
aims to analyze the pathogenesis, histopathological features, and clinical significance of NAFLD,
with emphasis on diagnostic strategies and therapeutic challenges.
Keywords:
hepatology, non-alcoholic fatty liver disease, steatosis, non-alcoholic steatohepatitis,
fibrosis, cirrhosis, histopathology
Introduction
Hepatology, as a distinct field of medicine, addresses the structural and functional disorders of
the liver. Among the broad spectrum of hepatological conditions, non-alcoholic fatty liver
disease has emerged as a global health concern due to its close association with obesity,
metabolic syndrome, and type 2 diabetes mellitus. NAFLD was once considered a benign
condition; however, increasing evidence demonstrates its progression to end-stage liver disease
and hepatocellular carcinoma in a significant proportion of patients.
Histologically, NAFLD is defined by lipid accumulation in hepatocytes exceeding 5% of the
liver weight, in the absence of secondary causes such as alcohol abuse, viral hepatitis, or
medication-induced injury. The importance of studying NAFLD lies not only in its prevalence
but also in its silent progression, as many patients remain asymptomatic until advanced stages.
Thus, early histological and clinical recognition is essential for effective intervention.
Methods
This article is based on a comprehensive review of peer-reviewed studies published between
2005 and 2024. Literature databases, including PubMed, Scopus, and Web of Science, were
searched using the keywords “NAFLD,” “NASH,” “liver fibrosis,” and “hepatopathology.”
Inclusion criteria comprised clinical trials, histopathological investigations, and meta-analyses on
NAFLD. Exclusion criteria involved case reports and non-English articles.
Histopathological evaluation relied on standard hematoxylin and eosin (H&E) staining and
Masson’s trichrome staining for fibrosis assessment. Biopsy samples were graded according to
the NAFLD Activity Score (NAS), which evaluates steatosis, lobular inflammation, and
hepatocyte ballooning. Statistical data were synthesized qualitatively to highlight the consistency
of histological findings across studies.
INTERNATIONAL JOURNAL
OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206
Volume 5, September ,2025
11
Results
Histopathological examination reveals that NAFLD encompasses a continuum of liver
alterations:
Simple Steatosis:
Characterized by macrovesicular fat accumulation in hepatocytes,
predominantly in the centrilobular (zone 3) region. Inflammation is absent or minimal.
Non-Alcoholic Steatohepatitis (NASH):
Defined by steatosis, lobular inflammation,
and hepatocyte ballooning. Mallory–Denk bodies may appear, indicating cytoskeletal damage.
Fibrosis:
Begins as perisinusoidal fibrosis in zone 3 and may progress to bridging
fibrosis connecting portal and central areas.
Cirrhosis:
Represents the advanced stage, with nodular regeneration, diffuse fibrosis,
and loss of normal lobular architecture.
Clinical studies demonstrate that approximately 25–30% of NAFLD patients progress to NASH,
while 10–20% develop advanced fibrosis or cirrhosis. Risk factors for progression include
obesity, insulin resistance, dyslipidemia, and genetic predisposition (such as PNPLA3 gene
variants).
Discussion
The pathogenesis of NAFLD is multifactorial and best explained by the “multiple-hit”
hypothesis. Insulin resistance leads to increased hepatic lipid uptake and de novo lipogenesis,
resulting in steatosis. Oxidative stress and mitochondrial dysfunction generate reactive oxygen
species, which induce lipid peroxidation and hepatocyte injury. This cascade activates Kupffer
cells and hepatic stellate cells, promoting inflammation and fibrosis.
Histopathological features of NAFLD not only provide diagnostic confirmation but also guide
prognosis and management. For example, ballooning degeneration is strongly associated with
progression to fibrosis, whereas isolated steatosis often remains stable. Fibrosis stage is the
strongest predictor of liver-related morbidity and mortality.
From a clinical perspective, NAFLD has implications beyond the liver. It is closely associated
with cardiovascular disease, chronic kidney disease, and extrahepatic malignancies. Therefore,
management requires a multidisciplinary approach focusing on lifestyle modification, weight
reduction, and control of metabolic comorbidities. Pharmacological options, including
pioglitazone and GLP-1 receptor agonists, show promise but are not yet universally
recommended.
Conclusion
Non-alcoholic fatty liver disease is a rapidly growing hepatological challenge, reflecting global
trends in obesity and metabolic syndrome. Histopathological assessment remains the gold
standard for diagnosis and staging, revealing a spectrum from simple steatosis to cirrhosis.
Understanding the mechanisms underlying its progression is critical for developing effective
INTERNATIONAL JOURNAL
OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206
Volume 5, September ,2025
12
preventive and therapeutic strategies. Given its systemic implications and silent course, NAFLD
deserves greater attention in both clinical hepatology and public health policy.
References
1.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of
non‐alcoholic fatty liver disease.
Hepatology.
2018;67(1):328–357.
2.
Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for
metabolic associated fatty liver disease.
Gastroenterology.
2020;158(7):1999–2014.
3.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of NAFLD.
Metabolism.
2016;65(8):1037–1046.
4.
Bedossa P. Pathology of non-alcoholic fatty liver disease.
Liver Int.
2017;37(Suppl
1):85–89.
5.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The
multiple parallel hits hypothesis.
Hepatology.
2010;52(5):1836–1846.
